Lancet Respiratory Medicine

Article	Citations
Postoperative CPAP after major abdominal surgery	846
Time to move away from an oxygen-centric model of pulmonary infarction?	566
Concerns regarding a suggested long COVID paradigm – Authors' reply	487
European Respiratory Society International Congress 2022	446
Video laryngoscopy is not the nemesis of direct laryngoscopy	396
Major gaps in childhood pneumonia research priorities remain	312
The course of action for effective anti-cytokine treatment in COVID-19	311
Correction to Lancet Respir Med 2024; 12: 129–40	293
Correction to Lancet Respir Med 2019; 7: 745–56	288
Rituximab for connective tissue disease-associated interstitial lung disease	275
Savolitinib in NSCLC: progress in the MET exon 14 journey	241
Broad protection from SARS-CoV-2 variants without antigen matching	233
GOLD report: 2022 update	228
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?	221
Predatory publishers appear in PubMed (and your inbox)	219
Predicted bodyweight—a misleading metric for tidal volume titration?	211
Australia bans engineered stone to prevent silicosis	206
Long COVID: systemic inflammation and obesity as therapeutic targets	194
The burden of tuberculosis in Libya	193
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	177
Eat or heat: fuel poverty and childhood respiratory health	176
Thoracentesis: an old story and some new sources	176
Interstitial lung disease: a decade of progress and hope	175
Chronic obstructive pulmonary disease: 10 years of precision-guided success	173
Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement	168

Opioids bring peace to patients with IPF cough	167
Impact of Myanmar's earthquake on respiratory health	167
FLiRTing with danger as SARS-CoV-2 variants evolve	164
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	156
US Senate committee investigates asthma inhaler prices	156
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	154
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop	154
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	154
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	153
Concerns about PRISm	150
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros	149
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	148
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	147
Advancing precision medicine for acute respiratory distress syndrome	146
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial	140
Cytokine adsorption and ECMO in patients with COVID-19	139
Genetic associations and lung function in IPF: unexpected answers, persistent questions	139
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply	139
Claudio Castanos—leader in cystic fibrosis care in Argentina	137
Priorities for NICE in health and social care	135
US EPA signals renewed regulatory scrutiny of toxic air pollution	134
Solid and semi-solid perspectives in thoracic surgery	133
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials	132
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts	130
Correction to Lancet Respir Med 2025; 13: 244–55	129
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges	128
Correction to Lancet Respir Med 2022; 10: 972–84	128
Correction to Lancet Respir Med 2021; 9: 1275–87	127
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	125
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta	125
Vaccination in the world's top athletes	125
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial	124
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials	122
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis	120
Improving lifelong respiratory health after preterm birth	120
Chronic cough as a disease: implications for practice, research, and health care	118
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study	117
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts	116
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial	116
Awake prone positioning in COVID-19: is tummy time ready for prime time?	116
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial	116
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study	115
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial	115
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis	110
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial	110
Trump administration decimates worker health oversight	109
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO	109
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co	109
Extracorporeal cardiopulmonary resuscitation: not why, but how	108
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s	108

Nintedanib for treating progressive fibrosing interstitial lung diseases	106
Association of SARS-CoV-2 infection and persistence with long COVID	106
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub	106
Trouble with promoting lung cancer screening in never-smokers	103
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial	103
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO	102
Venus and Mars: chest wall deformity and thoracic disease	102
COPD: a complex, multifactorial, but preventable disease?	101
Underappreciated causes of obstructive lung disease	101
Spirometry in female individuals – Authors' reply	100
Correction to Lancet Respir Med 2023; 11: 1064–74	100
Unveiling a hidden phenotype of early tuberculosis	98
Health effects from climate-driven events: lessons learnt	98
COP27 Climate Change Conference: urgent action needed for Africa and the world	95
Developments and priorities in bronchiectasis research	94
Realignment of clinical research after the COVID-19 era	93
Liberal or restrictive transfusion for VV ECMO	93
Tackling tuberculosis: what lies beneath the surface?	92
Opioid use and sleep apnoea	92
Clean air, climate targets, and respiratory health in Europe	91
Choice overload for RSV prevention—how to form your opinion	90
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma	89
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial	87
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing	87
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic	87
Prevalence of sleep-disordered breathing in an African general population: The Benin Society and Sleep (BeSAS) study	86
Predicting the future risk of lung cancer: development, and internal and external validation of the CanPredict (lung) model in 19·67 million people and evaluation of model performance against seven ot	86
Pre-COPD: an evolving concept with practice potential	86
Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials	86
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial	86
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study	85
Early-life respiratory syncytial virus disease and long-term respiratory health	85
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis	84
The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study	83
Correction to Lancet Respir Med 2021; published online June 18. https://doi.org/10.1016/S2213-2600(21)00089-8	82
Society of Critical Care Medicine Critical Care Congress 2023	79
SIMPLIFYing cystic fibrosis treatment in a post-modulator era	79
E-cigarette company tactics in sports advertising	78
Treating acute respiratory illness: the need to be proactive	77
The recent explosion in snortable energy powder consumption	77
Correction to Lancet Respir Med 2022; published online Feb 25. https://doi.org/10.1016/S2213-2600(22)00045-5	76
Collateral caring	75
Time-dependent bias when analysing COVID-19-associated pulmonary aspergillosis – Authors' reply	74
COVID-19—an infectious disease in the top five causes of death in Australia	74
Wildfires in southern California: concerns for lung health	73
The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP-CT): a multicentre, randomised, double-blind, controlled trial	71
Home monitoring in interstitial lung diseases	69
Long-term outcomes of early exposure to repeated general anaesthesia in children with cystic fibrosis (CF-GAIN): a multicentre, open-label, randomised controlled phase 4 trial	69
Managing tuberculosis before the onset of symptoms	68
Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS): a randomised, double-blind, placebo-controlled trial	66
Extracorporeal membrane oxygenation in adults receiving haematopoietic cell transplantation: an international expert statement	65
Breathing barriers: bridging lung health, research, and awareness	65
Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from tw	65
Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study	65
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis	63
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial	63
Sanjay Ramakrishnan—several lucky turns to arrive at COPD	62
Pioneering a paradigm shift in asthma management: remission as a treatment goal	62
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial	62
E-cigarettes for smoking reduction: a piece of the public health puzzle	61
NUTRIREA-3: where to next?	60
Moving forward in IPF: lessons learned from clinical trials	59
Cardiac and vascular serious adverse events following tixagevimab–cilgavimab	59
Rise in group A streptococcal infections in England	59
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicent	58
Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia	58
Reframing sepsis immunobiology for translation: towards informative subtyping and targeted immunomodulatory therapies	58
Continuing ECMO with no possible transition to recovery or transplant	57
The importance of post-tuberculosis morbidity in high-income countries	55
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled c	54
Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial	53
Trial emulation with observational data in cystic fibrosis	53
Tackling the global burden of lung disease through prevention and early diagnosis	52
Waning immunity to SARS-CoV-2: implications for vaccine booster strategies	52
Common and rare variants and survival in idiopathic pulmonary fibrosis	51
General population-based lung function trajectories over the life course: an accelerated cohort study	51
What is adequate preoxygenation? – Authors' reply	51
Do B cells rather than eosinophils drive chronic rhinosinusitis with nasal polyps?	51
Correction to Lancet Respir Med 2025; published online July 10. https://doi.org/10.1016/S2213-2600(25)00125-0	50
Continued enteral nutrition until extubation compared with fasting before extubation in patients in the intensive care unit: an open-label, cluster-randomised, parallel-group, non-inferiority trial	50

Weaning from mechanical ventilation in intensive care units across 50 countries (WEAN SAFE): a multicentre, prospective, observational cohort study	49
Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: a latent class analysis	49
Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multi	49
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial	48
Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and	48
Postoperative CPAP after major abdominal surgery – Authors' reply	47
US Senate announces planned gun reforms after latest school shooting	47
Lifting the veil on humour and anaesthetics	47
The upcoming influenza season and protection from vaccines	45
Guidelines might help reduce the burden of asthma in African children	44
Flavia Machado—a Latin American leader in sepsis	44
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO – Authors' reply	44
European Lung Cancer Congress 2024	43
Community-acquired pneumonia: the best candidates for clarithromycin	43
Correction to Lancet Respir Med 2023; published online Feb 3. https://doi.org/10.1016/S2213-2600(22)00491-X	43
Neomi Shah—cracking the conundrum of sleep disorders	43
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised,	42
ECMO: more than just a bridge over troubled waters?	42
Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts	42
Changes in rates of prescriptions for inhaled corticosteroids during the COVID-19 pandemic	42
Perioperative lung expansion and pulmonary outcomes after abdominal surgery	42
Reflections 5 years on from the approval of ETI therapy	42
Use of lung-cancer trends for global and public health priorities	42
Misconceptions regarding symptoms of sarcoidosis	42
Stubble: the Farmer's Bane	42
Oral corticosteroids for acute preschool wheeze	41
Patient in her 70s with COPD and asthma improving significantly since using monoclonal antibody dupilumab	41
Surviving sepsis with multiple serious complications	40
Correction to Lancet Respir Med 2024; 12: 544–55	40
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial	40
Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19	39
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomi	39
Chronic respiratory disease in Indigenous peoples: a framework to address inequity and strengthen respiratory health and health care globally	38
Surviving COVID-19: a familiar road to recovery?	38
Fighting sepsis: still a long way to go	37
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study	37
International guideline recommendations and eligibility criteria for home oxygen therapy	37
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management	36
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled,	36
Effect of non-invasive ventilation after extubation in critically ill patients with obesity in France: a multicentre, unblinded, pragmatic randomised clinical trial	36
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial	36
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study	36
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study	36
It is time to include real-world effectiveness data on medicinal product labels	36
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	35
Discussions on VT4COVID	35
US EPA strengthens PM2·5 air pollution limits	35
Remdesivir saves lives. Were 3 years needed to learn that?	35
Lockdown as the mother of invention: disruptive technology in a disrupted time	35
A leap forward in assessing host-directed therapies for tuberculosis	34
Correction Lancet Respir Med 2022; 10: 937–48	34
C-reactive protein-guided treatment in pneumonia: charting a personalised approach – Authors’ reply	34
Concerns regarding a suggested long COVID paradigm	34
Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	33
Correction to Lancet Respir Med 2025; 13: 318–26	33
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	33
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	32
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 tria	32
Home-based monitoring in chronic respiratory diseases: in search of Panacea	32
Unseen collateral damage: tackling preventable morbidity and mortality in family members of ICU decedents	31
Convalescent plasma in outpatients with COVID-19	31
Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity – Authors' reply	31
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	31
Arrival of biosimilars in respiratory medicine: towards improved access to biologics for patients	31
The passage of Ireland's Human Tissue Act: challenges, consequences, and cross-border cooperation	30
Air pollution, climate change, and lung health in Europe	30
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial	29
How Glasgow's 1957 tuberculosis screening programme could help countries today	29
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	29
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	29
Tuberculosis prevalence: beyond the tip of the iceberg	29
The carbon footprint of inhaled medications in Australia	28
Philip Morris International purchases Vectura	28
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-	28
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	28
Time to move away from an oxygen-centric model of pulmonary infarction? – Authors' reply	28
Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care	28
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	28
Concerning the use of aminoglycosides in ventilator-associated pneumonia – Authors' reply	28
Volcanic eruption in Tonga and effects on respiratory health	27
Addressing the origins and health effects of small lungs	27
Trouble with promoting lung cancer screening in never-smokers – Authors' reply	27
The Wuhan lockdown	27
The future of paediatric acute respiratory distress syndrome	27
Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa	26
Correction to Lancet Respir Med 2022; 10: 327–36	26
Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study	26
Living with spinal muscular atrophy while working in critical care	26
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts	26
Treatment strategy for EGFR mutated NSCLC	25
COVID-19-related ARDS: one disease, two trajectories, and several unanswered questions	25
Chronic obstructive pulmonary disease: new therapies and old needs	25
Effects of SARS-CoV-2 on prenatal lung growth assessed by fetal MRI	25
European Respiratory Society International Congress 2024	25
Navigating uncertainty: asthma biologics during pregnancy	24